

# ICMJE DISCLOSURE FORM

Date: 27, April, 2021

Your Name: Li-Hong Wu

Manuscript Title: Dimensions of the optic chiasm: ultrasound quantitative comparison between fetuses with anophthalmia/microphthalmia and normal fetuses

Manuscript number (if known): QIMS-21-151

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|                                                           |                                                                                                                                                                                | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| <b>Time frame: Since the initial planning of the work</b> |                                                                                                                                                                                |                                                                                              |                                                                                     |
| 1                                                         | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | National Natural Science Foundation of China, No. 81701459                                   |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
| <b>Time frame: past 36 months</b>                         |                                                                                                                                                                                |                                                                                              |                                                                                     |
| 2                                                         | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                                       | None                                                                                         |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |

|    |                                                                                                              |           |  |
|----|--------------------------------------------------------------------------------------------------------------|-----------|--|
| 3  | Royalties or licenses                                                                                        | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 4  | Consulting fees                                                                                              | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 6  | Payment for expert testimony                                                                                 | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 7  | Support for attending meetings and/or travel                                                                 | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 8  | Patents planned, issued or pending                                                                           | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board                                            | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 11 | Stock or stock options                                                                                       | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 13 | Other financial or non-financial interests                                                                   | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |

**Please summarize the above conflict of interest in the following box:**

I have no conflicts of interest to declare

**Please place an “X” next to the following statement to indicate your agreement:**

**X I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

# ICMJE DISCLOSURE FORM

Date: 27, April, 2021

Your Name: Qiao zheng

Manuscript Title: Dimensions of the optic chiasm: ultrasound quantitative comparison between fetuses with anophthalmia/microphthalmia and normal fetuses

Manuscript number (if known): QIMS-21-151

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|                                                           |                                                                                                                                                                                | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| <b>Time frame: Since the initial planning of the work</b> |                                                                                                                                                                                |                                                                                              |                                                                                     |
| 1                                                         | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | National Natural Science Foundation of China, No. 81701459                                   |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
| <b>Time frame: past 36 months</b>                         |                                                                                                                                                                                |                                                                                              |                                                                                     |
| 2                                                         | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                                       | None                                                                                         |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |

|    |                                                                                                              |           |  |
|----|--------------------------------------------------------------------------------------------------------------|-----------|--|
| 3  | Royalties or licenses                                                                                        | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 4  | Consulting fees                                                                                              | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 6  | Payment for expert testimony                                                                                 | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 7  | Support for attending meetings and/or travel                                                                 | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 8  | Patents planned, issued or pending                                                                           | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board                                            | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 11 | Stock or stock options                                                                                       | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 13 | Other financial or non-financial interests                                                                   | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |

**Please summarize the above conflict of interest in the following box:**

I have no conflicts of interest to declare

**Please place an “X” next to the following statement to indicate your agreement:**

**X I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

# ICMJE DISCLOSURE FORM

Date: 27, April, 2021

Your Name: Miao He

Manuscript Title: Dimensions of the optic chiasm: ultrasound quantitative comparison between fetuses with anophthalmia/microphthalmia and normal fetuses

Manuscript number (if known): QIMS-21-151

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|                                                           |                                                                                                                                                                                | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| <b>Time frame: Since the initial planning of the work</b> |                                                                                                                                                                                |                                                                                              |                                                                                     |
| 1                                                         | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | National Natural Science Foundation of China, No. 81701459                                   |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
| <b>Time frame: past 36 months</b>                         |                                                                                                                                                                                |                                                                                              |                                                                                     |
| 2                                                         | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                                       | <u>None</u>                                                                                  |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |

|    |                                                                                                              |           |  |
|----|--------------------------------------------------------------------------------------------------------------|-----------|--|
| 3  | Royalties or licenses                                                                                        | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 4  | Consulting fees                                                                                              | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 6  | Payment for expert testimony                                                                                 | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 7  | Support for attending meetings and/or travel                                                                 | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 8  | Patents planned, issued or pending                                                                           | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board                                            | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 11 | Stock or stock options                                                                                       | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 13 | Other financial or non-financial interests                                                                   | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |

**Please summarize the above conflict of interest in the following box:**

I have no conflicts of interest to declare

**Please place an “X” next to the following statement to indicate your agreement:**

**X I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

# ICMJE DISCLOSURE FORM

Date: 27, April, 2021

Your Name: Li-He Zhang

Manuscript Title: Dimensions of the optic chiasm: ultrasound quantitative comparison between fetuses with anophthalmia/microphthalmia and normal fetuses

Manuscript number (if known): QIMS-21-151

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|                                                           |                                                                                                                                                                                | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| <b>Time frame: Since the initial planning of the work</b> |                                                                                                                                                                                |                                                                                              |                                                                                     |
| 1                                                         | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | National Natural Science Foundation of China, No. 81701459                                   |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
| <b>Time frame: past 36 months</b>                         |                                                                                                                                                                                |                                                                                              |                                                                                     |
| 2                                                         | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                                       | None                                                                                         |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |

|    |                                                                                                              |           |  |
|----|--------------------------------------------------------------------------------------------------------------|-----------|--|
| 3  | Royalties or licenses                                                                                        | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 4  | Consulting fees                                                                                              | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 6  | Payment for expert testimony                                                                                 | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 7  | Support for attending meetings and/or travel                                                                 | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 8  | Patents planned, issued or pending                                                                           | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board                                            | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 11 | Stock or stock options                                                                                       | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 13 | Other financial or non-financial interests                                                                   | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |

**Please summarize the above conflict of interest in the following box:**

I have no conflicts of interest to declare

**Please place an “X” next to the following statement to indicate your agreement:**

**X I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

# ICMJE DISCLOSURE FORM

Date: 27, April, 2021

Your Name: Liu Du

Manuscript Title: Dimensions of the optic chiasm: ultrasound quantitative comparison between fetuses with anophthalmia/microphthalmia and normal fetuses

Manuscript number (if known): QIMS-21-151

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|                                                           |                                                                                                                                                                                | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| <b>Time frame: Since the initial planning of the work</b> |                                                                                                                                                                                |                                                                                              |                                                                                     |
| 1                                                         | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | National Natural Science Foundation of China, No. 81701459                                   |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
| <b>Time frame: past 36 months</b>                         |                                                                                                                                                                                |                                                                                              |                                                                                     |
| 2                                                         | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                                       | None                                                                                         |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |

|    |                                                                                                              |           |  |
|----|--------------------------------------------------------------------------------------------------------------|-----------|--|
| 3  | Royalties or licenses                                                                                        | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 4  | Consulting fees                                                                                              | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 6  | Payment for expert testimony                                                                                 | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 7  | Support for attending meetings and/or travel                                                                 | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 8  | Patents planned, issued or pending                                                                           | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board                                            | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 11 | Stock or stock options                                                                                       | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 13 | Other financial or non-financial interests                                                                   | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |

**Please summarize the above conflict of interest in the following box:**

I have no conflicts of interest to declare

**Please place an “X” next to the following statement to indicate your agreement:**

**X I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

# ICMJE DISCLOSURE FORM

Date: 27, April, 2021

Your Name: Hong-Ning Xie

Manuscript Title: Dimensions of the optic chiasm: ultrasound quantitative comparison between fetuses with anophthalmia/microphthalmia and normal fetuses

Manuscript number (if known): QIMS-21-151

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|                                                           |                                                                                                                                                                                | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| <b>Time frame: Since the initial planning of the work</b> |                                                                                                                                                                                |                                                                                              |                                                                                     |
| 1                                                         | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | National Natural Science Foundation of China, No. 81701459                                   |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
| <b>Time frame: past 36 months</b>                         |                                                                                                                                                                                |                                                                                              |                                                                                     |
| 2                                                         | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                                       | None                                                                                         |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |
|                                                           |                                                                                                                                                                                |                                                                                              |                                                                                     |

|    |                                                                                                              |           |  |
|----|--------------------------------------------------------------------------------------------------------------|-----------|--|
| 3  | Royalties or licenses                                                                                        | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 4  | Consulting fees                                                                                              | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 6  | Payment for expert testimony                                                                                 | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 7  | Support for attending meetings and/or travel                                                                 | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 8  | Patents planned, issued or pending                                                                           | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board                                            | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 11 | Stock or stock options                                                                                       | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |
| 13 | Other financial or non-financial interests                                                                   | ____ None |  |
|    |                                                                                                              |           |  |
|    |                                                                                                              |           |  |

**Please summarize the above conflict of interest in the following box:**

I have no conflicts of interest to declare

**Please place an “X” next to the following statement to indicate your agreement:**

**X I certify that I have answered every question and have not altered the wording of any of the questions on this form.**